Our study found that personalized treatment for HF patients according to their genotypes in VKORC1 and UGT1A6 gene polymorphisms could help clinicians to identify recommended doses of antiplatelet (aspirin) and anticoagulant (warfarin) drugs. This evidence concerns the gene UGT1A6 and hydrops fetalis.